What is the best course of action for managing a 48-year-old male patient's ADHD and anxiety, considering his history of excessive sweating on medication, essential hypertension, obesity, and history of sleep apnea, while currently on lisdexamfetamine (Vyvanse) 40 mg daily?

Management of ADHD and Anxiety in a 48-Year-Old Male with Hyperhidrosis, Hypertension, and Obesity

Continue Lisdexamfetamine 40 mg Daily for ADHD

Continue lisdexamfetamine (Vyvanse) 40 mg daily as your patient reports clear functional benefit with improved motivation and task completion, and this dose remains within the therapeutic range for adults (30-70 mg/day maximum). 1

Rationale for Continuing Current ADHD Treatment

• Lisdexamfetamine demonstrates 70-80% response rates in adults with ADHD when properly dosed, and your patient is experiencing meaningful improvement in executive function 2, 3
• The current 40 mg dose is mid-range; maximum approved dosing is 70 mg/day, allowing room for upward titration if needed 1
• Lisdexamfetamine provides once-daily dosing with 12-14 hour symptom coverage, which is critical for consistent all-day ADHD management 4, 5
• The prodrug formulation has lower abuse potential compared to immediate-release amphetamines, making it appropriate for long-term use 6, 5

Critical Cardiovascular Monitoring Required

Given this patient's essential hypertension (on lisinopril 10 mg) and obesity (BMI ~43), you must implement systematic blood pressure and pulse monitoring at every visit, as stimulants can elevate both parameters. 1

• Obtain home BP/HR log several times weekly at varied times before next follow-up 2
• Lisdexamfetamine should be avoided in patients with uncontrolled hypertension or symptomatic cardiovascular disease 1
• If BP becomes uncontrolled, coordinate with primary care to intensify antihypertensive therapy rather than discontinuing effective ADHD treatment 2
• The FDA label explicitly warns to avoid use in patients with serious cardiac disease, cardiomyopathy, or coronary artery disease 1

---

Do Not Restart Sertraline—Pursue Alternative Anxiety Management

Do not restart sertraline 50 mg given the patient's primary concern about persistent hyperhidrosis that began on sertraline and has not fully resolved 2 weeks after discontinuation. 7

Order GeneSight Pharmacogenomic Testing

• GeneSight testing will guide selection of an alternative anxiety medication with lower risk of hyperhidrosis 2
• Review results at 4-6 week follow-up to determine optimal SSRI or alternative agent 2

Monitor Anxiety Severity Over Next 4-6 Weeks

• The patient reports increased anxiety since stopping sertraline but denies panic attacks 7
• Early data from 2002 showed that comorbid anxiety does not contraindicate stimulant use; in fact, the MTA study demonstrated that ADHD patients with comorbid anxiety had increased treatment response to stimulants 7
• Stimulant treatment alone may indirectly reduce anxiety by improving ADHD-related functional impairment 8

If Anxiety Becomes Acutely Impairing Before GeneSight Results

• Consider short-term PRN anxiolytic with careful counseling on sedation risks, but reassess promptly 2
• Do not prescribe benzodiazepines for chronic anxiety in ADHD patients due to disinhibiting effects and lack of evidence for long-term use 8

Strongly Recommend Restarting Psychotherapy

• Cognitive-behavioral therapy (CBT) targeting social anxiety and avoidance behaviors (phone calls, fear of criticism) is the most extensively studied and effective psychotherapy for adult ADHD with comorbid anxiety 2
• The patient completed 2 years of therapy with benefit (fewer panic attacks) but stopped last month when therapist changed jobs 2
• While the patient wants to "trial holding off" temporarily, untreated social anxiety will continue to impair functioning across multiple domains 2
• CBT is more effective when combined with medication rather than used as monotherapy 2

---

Address Persistent Hyperhidrosis

Monitor Sweating Over Next 4-6 Weeks Off Sertraline

• The patient reports variable daytime sweating that persists 2 weeks after stopping sertraline, though "definitely less annoying" than initially 2
• Hyperhidrosis may be medication-induced (from sertraline or lisdexamfetamine) or may have medical contributors 2

Coordinate with Primary Care for Further Evaluation

• If sweating persists or worsens at 4-6 week follow-up, coordinate with primary care physician to evaluate medical contributors 2
• Recent labs reportedly normal (glucose, A1c, insulin, cortisol, thyroid function), but verify whether vitamin B12 and vitamin D were checked 2
• Request outside labs from primary care and review for any abnormalities 2

Consider Lisdexamfetamine as Potential Contributor

• Amphetamines commonly cause increased sweating as an adverse effect 1
• However, do not discontinue effective ADHD treatment solely due to sweating unless it becomes intolerable, as untreated ADHD is associated with increased risk of accidents, substance abuse, and functional impairment 2
• If sweating is definitively attributed to lisdexamfetamine and remains intolerable despite medical management, consider switching to methylphenidate class (which may have different side effect profile) or non-stimulant alternatives 7, 2

---

Urine Drug Screen and Controlled Substance Monitoring

• Complete urine drug screen within next few months per controlled-substance monitoring requirements 2
• This is standard practice for Schedule II stimulant prescribing and should be framed as routine monitoring, not suspicion of misuse 2

---

Weight Management and Metabolic Considerations

Address 40-Pound Weight Gain Since Smoking Cessation

• Current weight 335 lb at 6'2" (BMI ~43) represents significant cardiovascular and metabolic risk 2
• Lisdexamfetamine substantially suppresses appetite (patient rarely eats breakfast, occasionally lunch, typically only dinner) 2
• Patient is tracking Weight Watchers points and applied for GLP-1 agonist coverage (denied due to cost) 2

Coordinate with Primary Care

• Encourage regular nutrition despite appetite suppression, as erratic eating patterns may worsen metabolic health 2
• Continue Weight Watchers program and explore alternative weight management options with primary care 2
• Lisdexamfetamine is not indicated for weight loss, and use of sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events 1

---

Follow-Up Plan

Schedule 4-6 Week Video Visit

• Review GeneSight pharmacogenomic results and select alternative anxiety medication if needed 2
• Review home BP/HR log to assess cardiovascular safety of continued lisdexamfetamine 2
• Assess anxiety severity and determine if pharmacological intervention is needed before psychotherapy restarts 2
• Evaluate hyperhidrosis trajectory and determine if further medical workup is warranted 2

Confirm Brand vs. Generic Lisdexamfetamine

• Patient should confirm with pharmacy whether current supply is brand (Vyvanse) vs. generic and report any efficacy differences 2
• Generic formulations may have different inactive ingredients affecting tolerability 2

---

Common Pitfalls to Avoid

• Do not discontinue effective ADHD treatment due to concerns about "taking medication forever"—untreated ADHD carries significant morbidity 2
• Do not restart sertraline without addressing the hyperhidrosis concern that led to discontinuation 7
• Do not assume anxiety will resolve without intervention—social anxiety requires targeted treatment (CBT ± medication) 2
• Do not ignore cardiovascular risk—this patient has multiple risk factors (hypertension, obesity, stimulant use) requiring systematic monitoring 1
• Do not prescribe immediate-release stimulants for "as-needed" use—ADHD requires consistent daily treatment 2